New pill combo aims to halt brain tumor growth
NCT ID NCT07652762
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This early-stage trial tests two oral drugs, IN10018 and dalpiciclib, in 24 adults with progressive meningiomas (brain tumors that have grown despite prior treatment). The study focuses on safety and finding the right dose, while also checking if the combination can shrink tumors or delay progression. Participants take both pills daily in 28-day cycles until the disease worsens or side effects become unacceptable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sanbo Brain Hospital, Capital Medical University
Beijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IN10018 (Ifebemtinib) and Dalpiciclib
What this could lead to
If this combination works, it could offer a new oral treatment option to slow or shrink progressive meningiomas that have not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so the main goal is safety, not effectiveness. The drugs may cause side effects or fail to control tumor growth.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.